Clearside Biomedical

Clearside Biomedical CROIC

Delisted

The Cash Return on Invested Capital (CROIC) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 66.08 %. In the previous year, Cash Return on Invested Capital (CROIC) was 125.14 % — a change of -47.20% (lower).

CROIC

66.08 %

YoY

-47.20%

Last updated:

Cash Return on Invested Capital (CROIC) of Clearside Biomedical is 2024 66.08 % . Cash Return on Invested Capital (CROIC) of Clearside Biomedical was 2023 125.14 % . It decreases by -47.20% lower compared to the previous year.

The Clearside Biomedical CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
-174.62 USD
Jan 1, 2018
-235.98 USD
Jan 1, 2019
-166.16 USD
Jan 1, 2020
-135.18 USD
Jan 1, 2021
-28.25 USD
Jan 1, 2022
-128.37 USD
Jan 1, 2023
125.14 USD
Jan 1, 2024
66.08 USD
The Clearside Biomedical CROIC history
YEARCROICYoY
66.08 %-47.20%
125.14 %-197.48%
-128.37 %+354.38%
-28.25 %-79.10%
-135.18 %-18.64%
-166.16 %-29.59%
-235.98 %+35.14%
-174.62 %+509.36%
-28.66 %-65.77%
-83.71 %-31.11%
-121.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Cash Return on Invested Capital (CROIC) of Clearside Biomedical is 66.08 % in 2024.

Cash Return on Invested Capital (CROIC) of Clearside Biomedical changed from 125.14 % to 66.08 %, representing a -47.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical